Mirum PharmaceuticalsMIRM
About: Mirum Pharmaceuticals Inc is a biopharmaceutical company focused on the identification, acquisition, development, and commercialization of novel therapies for debilitating rare and orphan diseases. Its product, Livmarli, a novel, orally administered, minimally-absorbed ileal bile acid transporter IBAT) inhibitor (IBATi), is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS). It is involved in the development of Maralixibat for the treatment of pediatric patients with progressive familial intrahepatic cholestasis, or PFIC, and Alagille syndrome, or ALGS. The company is also involved in the development of volixibat for the treatment of adult patients with cholestatic liver diseases.
Employees: 334
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
42% more first-time investments, than exits
New positions opened: 34 | Existing positions closed: 24
29% more repeat investments, than reductions
Existing positions increased: 85 | Existing positions reduced: 66
12% more capital invested
Capital invested by funds: $2.19B [Q4 2024] → $2.44B (+$253M) [Q1 2025]
4% more funds holding
Funds holding: 204 [Q4 2024] → 212 (+8) [Q1 2025]
0.1% more ownership
Funds ownership: 110.36% [Q4 2024] → 110.46% (+0.1%) [Q1 2025]
0% more funds holding in top 10
Funds holding in top 10: 11 [Q4 2024] → 11 (+0) [Q1 2025]
49% less call options, than puts
Call options by funds: $2.43M | Put options by funds: $4.78M
Research analyst outlook
3 Wall Street Analysts provided 1 year price targets over the past 3 months
3 analyst ratings
HC Wainwright & Co. Swayampakula Ramakanth | 47%upside $73 | Buy Assumed | 19 May 2025 |
Raymond James Steven Seedhouse | 55%upside $77 | Strong Buy Maintained | 13 May 2025 |
JMP Securities Jonathan Wolleben | 53%upside $76 | Market Outperform Maintained | 9 May 2025 |
Financial journalist opinion
Based on 3 articles about MIRM published over the past 30 days
